New medical treatment options and strategies to assess clinical outcome in soft-tissue sarcoma.
about
LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potentialOptimizing clinical care in patients with advanced soft tissue sarcoma: a phase II study of a new schedule of high-dose continuous infusion ifosfamide and doxorubicin combination.Systemic therapy in primary angiosarcoma of the spleen.Pazopanib: a promising new agent in the treatment of soft tissue sarcomas.Synovial sarcoma individual chemotherapy directed by collagen gel droplet embedded culture drug sensitivity test: A case report
P2860
New medical treatment options and strategies to assess clinical outcome in soft-tissue sarcoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
New medical treatment options ...... utcome in soft-tissue sarcoma.
@en
New medical treatment options ...... utcome in soft-tissue sarcoma.
@nl
type
label
New medical treatment options ...... utcome in soft-tissue sarcoma.
@en
New medical treatment options ...... utcome in soft-tissue sarcoma.
@nl
prefLabel
New medical treatment options ...... utcome in soft-tissue sarcoma.
@en
New medical treatment options ...... utcome in soft-tissue sarcoma.
@nl
P2860
P356
P1476
New medical treatment options ...... utcome in soft-tissue sarcoma.
@en
P2093
Bernd Kasper
Thomas Schmitt
P2860
P304
P356
10.1586/ERA.09.64
P577
2009-08-01T00:00:00Z